by Clinical Neuropsychologist | Monday, September 23, 2024 | Dementia
Abstract INTRODUCTION Subjective cognitive decline (SCD) may be an early marker of Alzheimer’s disease (AD) pathology. Until recently, it was impossible to measure biomarkers specific for α-synuclein pathology; therefore, its association with subjective reports...
by Clinical Neuropsychologist | Monday, September 23, 2024 | Dementia
Abstract Early diagnosis is crucial to treatment success. This is especially relevant for Alzheimer’s disease (AD), with its protracted preclinical phase. Most health care systems do not have the resources to conduct large-scale AD screenings in middle-aged...
by Clinical Neuropsychologist | Monday, September 23, 2024 | Dementia
Abstract INTRODUCTION The microglial receptor triggering receptor expressed on myeloid cells 2 (TREM2) is a major risk factor for Alzheimer’s disease (AD). Experimentally, Trem2 deficiency affects parenchymal amyloid beta (Aβ) deposition. However, the role of...
by Clinical Neuropsychologist | Sunday, September 22, 2024 | Dementia
Abstract The emergence of the United States Food and Drug Administration (FDA)-approved amyloid-targeting therapies for Alzheimer’s disease challenges clinicians and healthcare providers with a transformative landscape. Effectively communicating the risks,...
by Clinical Neuropsychologist | Saturday, September 21, 2024 | Dementia
Dementia, Volume 24, Issue 3, Page 552-576, April 2025. Aim:to explore the range of cultural understandings of dementia held by people providing nursing care globally.Background:There is a worldwide shortage of nurses and healthcare workers, resulting in extensive...
